News OM1 Launches MS Registry for Use in Research, Trial Planning OM1 Launches MS Registry for Use in Research, Trial Planning by Mary Chapman | July 16, 2021 Share this article: Share article via email Copy article link Maksym Dykha/Shutterstock OM1, a technology company focused on chronic conditions, announced that it has launched a multiple sclerosis (MS) registry to generate data that may ultimately be used to improve care and develop treatments for the disease. The OM1 registry is being touted as the largest, most representative MS data registry available for analytics, licensing, and collaboration. Registries typically use observational study methods to collect data that can be used to measure certain outcomes for a particular disease or condition. They typically serve scientific, clinical, or policy purposes. OM1ās continually updated registry is reported to have an enrollment of more than 20,000 patients, who are being prospectively followed by neurologists for clinical and lab data, including longitudinal outcomes, relapses, treatment responses, subtype data where applicable, and disability scores. āThe high availability and depth of the registry data enables healthcare stakeholders to answer important questions around natural history, disease progression, treatment response, and outcomes,ā Richard Gliklich, MD, the company’s CEO, said in a press release. For modeling, analytics, and other investigative purposes, scientists may also obtain data from another 460,000 MS patients in the companyās Real-World Data Cloud. Through the registry, users to have access to deep clinical MS data, research-grade information, analytics-ready data, and longitudinal data (mean follow up at 5.5 years). These data, OM1 reported, are a source ofĀ unique insights into a patient’s journey, disease activity, treatment effectiveness, treatment patterns, care pathways, healthcare prescriber patterns, and others. According to OM1, the registry can be used to plan better clinical trials; to better understand the treatment market as well as unmet needs, outcomes, and behavior; to find patients and explore subtypes; and to analyze causes of gaps in care, treatment, and diagnosis. Recommended Reading July 9, 2021 Columns by John Connor Lockdown Blues: Well That Was a Close Shave! āEarly diagnosis and effective treatment are the best way to reduce the damaging effects and to improve an MS patientās quality of life,ā Gliklich said It is estimated that about 1 million people in the U.S. have MS. OM1 uses big clinical data and artificial intelligence to better understand, compare, and predict patient outcomes. The company has a special focus on chronic diseases like MS. Print This Page About the Author Mary Chapman Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. Sheās won a Society of Professional Journalists award for outstanding reporting. Tags artificial intelligence
August 10, 2023 News by Andrea Lobo, PhD Neuro Night event to raise funds for neurological care, research
March 1, 2023 News by Marisa Wexler, MS ACTRIMS 2023: MS clinical research lacks diversity, representation
August 24, 2022 News by Mary Chapman New MS Grant Winners to Explore Disease Risk, Prevalence in Australia